/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a major provider of life sciences tools and diagnostics. With a market cap of $11.45 billion, Bio-Techne is recognized for its comprehensive solutions in protein analysis, cell and gene therapy, and molecular diagnostics. The company’s innovative approach to biotechnology and clinical research enables its clients to advance scientific discoveries and develop effective treatments, helping to shape the future of healthcare and life sciences.
Shares of TECH have underperformed the broader market over the past year. The stock has declined 7.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 27.8%. In 2024, the stock is down 5.8%, while SPX has gained 17.8% on a YTD basis.
Narrowing the focus, TECH's underperformance is evident when measured against the VanEck Biotech ETF (BBH). The exchange-traded fund has gained 10.5% on a YTD basis.
On Aug. 7, Bio-Techne saw its shares drop over 9% after reporting Q4 net sales of $306.10 million, which fell short of the consensus estimate of $307.10 million.
For the current fiscal year, ending in June 2025, analysts expect TECH’s EPS to grow 7% to $1.68 on a diluted basis. The company's earnings surprise history is mixed. It beat the consensus estimate in two of the last four quarters while missing on two other occasions.
Among the 13 analysts covering TECH stock, the consensus rating is a “Strong Buy.” That’s based on 10 “Strong Buy” ratings and three “Holds.”
On Aug. 16, Sung Ji Nam from Scotiabank maintained a “Buy” rating on Bio-Techne, with a price target of $83, implying a potential upside of 14.2% from current levels.
The mean price target of $82 represents a 12.9% premium compared to TECH’s current price levels. The Street-high price target of $95 suggests an upside potential of 30.8%.
On the date of publication, Rashmi Kumari did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
